A novel recessive 15-hydroxyprostaglandin dehydrogenase mutation in a family with primary hypertrophic osteoarthropathy

Primary Hypertrophic Osteoarthropathy: An Update on Patient Features and Treatment

“…Nevertheless, a patient with JIA, nonresponder to DMARD and biological therapies, and with a better response to NSAID, should be considered as having another disease and investigated for further clinical signs. Indeed, HPGD and SLCO2A1 patients usually experience some positive effects on joint pain and swelling while being treated with NSAID 5,12,16,17,18 , but it is uncertain if either the use of indomethacin compared with ibuprofen could provide better results clinically, as for patient 3, or if the phenotype of this patient is milder as a consequence of being female.…”

A novel mutation in the HPGD gene causing primary hypertrophic osteoarthropathy with digital clubbing in a Pakistani family

“…To date, five missense/nonsense mutations (Seifert et al., ; Bergmann et al., ; Uppal et al., ; Yuksel‐Konuk et al., ; Bergmann et al., ; Present study), two splicing mutations (Sinibaldi et al., ; Diggle et al., ), three deletions (Seifert et al., ; Uppal et al., ; Erken et al., ; Tuysuz et al., ; Liu et al., ), and a single insertion deletion (indel) (Uppal et al., ) have been identified in the HPDG gene that cause PHO in various ethnic groups. Tariq et al.…”

Effectiveness of non-steroidal anti-inflammatory drugs among patients with primary hypertrophic osteoarthropathy: A systematic review

“…All 26 studies were case reports which included a total of 54 patients. The studies were conducted in India [16,17,[19][20][21][22], Spain [12,23], Japan [10,21,24,25], Germany [26,27], Italy [14,28,29], Turkey [30][31][32], Brazil [11], Tunisia [33], Portugal [34], Switzerland [35], Poland [35], Czech Republic [35], Australia [35], and UK [13]. One study did not report the study location [7].…”